Figure 5.

Immunometabolism subtypes correlate with immunotherapy. (A, B) Heatmaps show the immune landscape and metabolism signatures of four immunometabolism subtypes in ccRCC prior to anti-PD-1 therapy (Baun et al.). (C) Percentages of four immunometabolism subtypes in responders and non-responders prior to anti-PD-1 therapy in ccRCC. (D, E) Stratification survival analysis of TMB <17 and TMB >17 across four subtypes in bladder cancer (IMvigor210 cohort). p-value is given by log-rank test. (F) Receiver operating characteristics of predicting the response of anti-PD-1 therapy in bladder cancer based on the TMB and immunometabolism subtypes.